

Mitotane, Plasma

# Overview

#### Useful For

Assessing compliance or making dosage adjustments for mitotane

#### **Method Name**

Gas Chromatography Mass Spectrometry (GC-MS) Confirmation with Quantitation

# NY State Available

Yes

# Specimen

#### **Specimen Type** Plasma Na Heparin

**Shipping Instructions** Ship specimen refrigerated.

Specimen Required Collection Container/Tube: Green top (sodium heparin) (Lithium heparin and PST/plasma gel tubes are not acceptable.) Submission Container/Tube: Plastic vial Specimen Volume: 1 mL Collection Instructions: Within 2 hours of collection, centrifuge and aliquot plasma into plastic vial.

# **Forms** <u>If not ordering electronically, complete, print, and send a Therapeutics Test Request</u> (T831) with the specimen.

# Specimen Minimum Volume

0.5 mL

#### Reject Due To

Gross	ОК
hemolysis	
Gross lipemia	Reject
Gross icterus	ОК

#### Specimen Stability Information

Specimen Type Temperat	re Time	Special Container
------------------------	---------	-------------------

**Test Definition: MITAN** 



Mitotane, Plasma

Plasma Na Heparin	Refrigerated (preferred)	21 days	
	Ambient	72 hours	
	Frozen	28 days	

# Clinical & Interpretive

#### **Clinical Information**

This test is intended for the use of therapeutic monitoring of the drug mitotane in patients being treated for adrenal carcinoma. Guidelines suggest monitoring mitotane serum/plasma levels every 2 to 3 weeks for the first 3 months. After reaching a plateau, the interval can be extended (eg, every 6 weeks). Mitotane is a key drug for the treatment of adrenal cortical carcinoma. Due to its narrow therapeutic window (14 to 20 mcg/mL), monitoring its concentration is crucially important.

#### **Reference Values**

Therapeutic: 14-20 mcg/mL

#### Interpretation

In the literature when mitotane is used to treat adrenocortical carcinoma, the maximum benefit is seen when plasma mitotane concentrations are between 14-20 mcg/mL.

#### Cautions

No significant cautionary statements

#### **Clinical Reference**

1. Feliu C, Cazaubon Y, Guillemin H, et al. Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up. Biomed Chromatogr. 2017;31(11):10.1002/bmc.3993. doi:10.1002/bmc.3993

2. Ando M, Hirabatake M, Yasui H, Fukushima S, Sugioka N, Hashida T. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. Biomed Chromatogr. 2020;34(3):e4776. doi:10.1002/bmc.4776

#### Performance

#### **Method Description**

After protein precipitation, mitotane is analyzed by gas chromatography with mass spectrometry.(Unpublished Mayo method)

# PDF Report

No

Day(s) Performed Tuesday, Thursday

#### Report Available



2 to 7 days

# **Specimen Retention Time**

14 days

# **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Superior Drive

# Fees & Codes

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

# **CPT Code Information**

80299

### LOINC<sup>®</sup> Information

Test ID	Test Order Name	Order LOINC <sup>®</sup> Value
MITAN	Mitotane, P	13626-7

Result ID	Test Result Name	Result LOINC <sup>®</sup> Value
621811	Mitotane, P	13626-7